• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Moving Beyond Minimization Trials in Kidney Transplantation.超越肾移植中的最小化试验
J Am Soc Nephrol. 2015 Dec;26(12):2898-901. doi: 10.1681/ASN.2015030245. Epub 2015 Apr 29.
2
Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.免疫稳定的肾移植受者停用他克莫司的不良后果。
J Am Soc Nephrol. 2015 Dec;26(12):3114-22. doi: 10.1681/ASN.2014121234. Epub 2015 Apr 29.
3
Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.接受基于他克莫司的免疫抑制方案随后早期转换为西罗莫司的肾移植受者中的亚临床病变和供体特异性抗体
Transplantation. 2015 Nov;99(11):2372-81. doi: 10.1097/TP.0000000000000748.
4
Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.从基于西罗莫司的免疫抑制方案中早期停用钙调神经磷酸酶抑制剂可稳定肾移植中的纤维化和转化生长因子-β信号通路。
Nephrology (Carlton). 2015 Mar;20(3):168-76. doi: 10.1111/nep.12368.
5
High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.在使用低剂量他克莫司免疫抑制方案的肾移植中，患者体内他克莫司的高变异性与更差的预后相关。
Transplantation. 2017 Feb;101(2):430-436. doi: 10.1097/TP.0000000000001129.
6
A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.一项肾移植的随机2×2析因临床试验：六个月后停用钙调神经磷酸酶抑制剂的无类固醇维持免疫抑制与肾功能改善及慢性组织病理学减轻相关。
PLoS One. 2015 Oct 14;10(10):e0139247. doi: 10.1371/journal.pone.0139247. eCollection 2015.
7
Adequate exposure to tacrolimus with sublingual administration in pediatric liver transplant patients.小儿肝移植患者经舌下给药充分暴露于他克莫司。
Int J Clin Pharmacol Ther. 2017 Apr;55(4):352-354. doi: 10.5414/CP202719.
8
Immunological risks of minimization strategies.最小化策略的免疫风险。
Transpl Int. 2015 Aug;28(8):901-10. doi: 10.1111/tri.12570. Epub 2015 Apr 9.
9
Calcineurin Inhibitor-Sparing Strategies in Renal Transplantation: Where Are We? A Comprehensive Review of the Current Evidence.肾移植中钙调神经磷酸酶抑制剂节约策略：我们目前的进展如何？对当前证据的全面综述
Exp Clin Transplant. 2016 Oct;14(5):471-483. doi: 10.6002/ect.2015.0283. Epub 2015 May 17.
10
Effect of Early Everolimus-Facilitated Reduction of Tacrolimus on Efficacy and Renal Function in De Novo Liver Transplant Recipients: 24-Month Results for the North American Subpopulation.早期依维莫司促进他克莫司减量对初发肝移植受者疗效和肾功能的影响：北美亚组的24个月结果
Transplantation. 2017 Feb;101(2):341-349. doi: 10.1097/TP.0000000000001524.

引用本文的文献

1
Early steroid withdrawal and kidney transplant outcomes in first-transplant and retransplant recipients.首次移植和再次移植受者的早期停用类固醇与肾移植结局
Nephrol Dial Transplant. 2025 Apr 1;40(4):662-670. doi: 10.1093/ndt/gfae218.
2
Inconsistencies in the association of clinical factors with the choice of early steroid withdrawal across kidney transplant centers: A national registry study.肾移植中心之间临床因素与早期停用类固醇选择之间关联的不一致性：一项全国性登记研究。
Clin Transplant. 2021 Feb;35(2):e14176. doi: 10.1111/ctr.14176. Epub 2020 Dec 12.
3
Eplet Mismatch Load and Occurrence of Donor-Specific Anti-HLA Antibodies, Rejection, and Graft Failure after Kidney Transplantation: An Observational Cohort Study.Eplet 错配负荷与供体特异性抗 HLA 抗体、排斥反应和肾移植后移植物失败的发生：一项观察性队列研究。
J Am Soc Nephrol. 2020 Sep;31(9):2193-2204. doi: 10.1681/ASN.2020010019. Epub 2020 Aug 6.
4
A Novel, Dose-Adjusted Tacrolimus Trough-Concentration Model for Predicting and Estimating Variance After Kidney Transplantation.一种新型的、剂量调整的他克莫司血药谷浓度模型，用于预测和估计肾移植后的变异性。
Drugs R D. 2019 Jun;19(2):201-212. doi: 10.1007/s40268-019-0271-2.
5
The Evaluation and Therapeutic Management of Hypertension in the Transplant Patient.移植患者高血压的评估与治疗管理
Curr Cardiol Rep. 2015 Nov;17(11):95. doi: 10.1007/s11886-015-0647-z.

本文引用的文献

1
The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival.II类人类白细胞抗原表位错配与不依从性对急性排斥反应和移植物存活的协同作用
Am J Transplant. 2015 Aug;15(8):2197-202. doi: 10.1111/ajt.13341. Epub 2015 Jun 11.
2
Adverse Outcomes of Tacrolimus Withdrawal in Immune-Quiescent Kidney Transplant Recipients.免疫稳定的肾移植受者停用他克莫司的不良后果。
J Am Soc Nephrol. 2015 Dec;26(12):3114-22. doi: 10.1681/ASN.2014121234. Epub 2015 Apr 29.
3
Firmly tilting the balance of clinical transplant immunity toward tolerance.坚定地将临床移植免疫的平衡倾向于耐受。
Am J Transplant. 2015 Mar;15(3):583-4. doi: 10.1111/ajt.13094.
4
OPTN/SRTR 2013 Annual Data Report: kidney.OPTN/SRTR 2013 年度数据报告：肾脏。
Am J Transplant. 2015 Jan;15 Suppl 2:1-34. doi: 10.1111/ajt.13195.
5
Early corticosteroid avoidance in kidney transplant recipients receiving ATG-F induction: 5-year actual results of a prospective and randomized study.肾移植受者接受 ATG-F 诱导时早期避免使用皮质类固醇：一项前瞻性随机研究的 5 年实际结果。
Am J Transplant. 2014 Nov;14(11):2556-64. doi: 10.1111/ajt.12866. Epub 2014 Sep 19.
6
Biomarkers for kidney transplant rejection.用于肾移植排斥反应的生物标志物。
Nat Rev Nephrol. 2014 Apr;10(4):215-25. doi: 10.1038/nrneph.2013.281. Epub 2014 Jan 21.
7
Is it time to give up with calcineurin inhibitors in kidney transplantation?是时候放弃肾移植中使用钙调神经磷酸酶抑制剂了吗？
World J Transplant. 2013 Jun 24;3(2):7-25. doi: 10.5500/wjt.v3.i2.7.
8
Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes.HLA Ⅱ类表位匹配：降低供者特异性抗体产生和改善预后的策略
Am J Transplant. 2013 Dec;13(12):3114-22. doi: 10.1111/ajt.12478. Epub 2013 Oct 25.
9
Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury.多中心验证尿 CXCL9 作为肾移植损伤的风险分层生物标志物。
Am J Transplant. 2013 Oct;13(10):2634-44. doi: 10.1111/ajt.12426. Epub 2013 Aug 22.
10
Evolving approaches of hematopoietic stem cell-based therapies to induce tolerance to organ transplants: the long road to tolerance.基于造血干细胞的治疗方法诱导对器官移植的耐受：通向耐受的漫长道路。
Clin Pharmacol Ther. 2013 Jan;93(1):36-45. doi: 10.1038/clpt.2012.201. Epub 2012 Oct 10.

Moving Beyond Minimization Trials in Kidney Transplantation.

作者信息

Matas Arthur J, Gaston Robert S

机构信息

Department of Surgery,

Comprehensive Transplant Institute, University of Alabama at Birmingham, Birmingham, Alabama.

出版信息

J Am Soc Nephrol. 2015 Dec;26(12):2898-901. doi: 10.1681/ASN.2015030245. Epub 2015 Apr 29.

DOI:10.1681/ASN.2015030245
PMID:25925686
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4657847/
Abstract
摘要